Literature DB >> 23742729

Role of CXCL13 in cigarette smoke-induced lymphoid follicle formation and chronic obstructive pulmonary disease.

Ken R Bracke1, Fien M Verhamme, Leen J M Seys, Claudie Bantsimba-Malanda, Danen Mootoosamy Cunoosamy, Ronald Herbst, Hamida Hammad, Bart N Lambrecht, Guy F Joos, Guy G Brusselle.   

Abstract

RATIONALE: The B cell-attracting chemokine CXCL13 is an important mediator in the formation of tertiary lymphoid organs (TLOs). Increased numbers of ectopic lymphoid follicles have been observed in lungs of patients with severe chronic obstructive pulmonary disease (COPD). However, the role of these TLOs in the pathogenesis of COPD remains unknown.
OBJECTIVES: By neutralizing CXCL13 in a mouse model of chronic cigarette smoke (CS) exposure, we aimed at interrogating the link between lymphoid follicles and development of pulmonary inflammation, emphysema, and airway wall remodeling.
METHODS: We first quantified and localized CXCL13 in lungs of air- or CS-exposed mice and in lungs of never smokers, smokers without airflow obstruction, and patients with COPD by reverse transcriptase-polymerase chain reaction, ELISA, and immunohistochemistry. Next, CXCL13 signaling was blocked by prophylactic or therapeutic administration of anti-CXCL13 antibodies in mice exposed to air or CS for 24 weeks, and several hallmarks of COPD were evaluated.
MEASUREMENTS AND MAIN RESULTS: Both mRNA and protein levels of CXCL13 were increased in lungs of CS-exposed mice and patients with COPD. Importantly, expression of CXCL13 was observed within B-cell areas of lymphoid follicles. Prophylactic and therapeutic administration of anti-CXCL13 antibodies completely prevented the CS-induced formation of pulmonary lymphoid follicles in mice. Interestingly, absence of TLOs attenuated destruction of alveolar walls and inflammation in bronchoalveolar lavage but did not affect airway wall remodeling.
CONCLUSIONS: CXCL13 is produced within lymphoid follicles of patients with COPD and is crucial for the formation of TLOs. Neutralization of CXCL13 partially protects mice against CS-induced inflammation in bronchoalveolar lavage and alveolar wall destruction.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23742729     DOI: 10.1164/rccm.201211-2055OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  39 in total

1.  Serpine2 deficiency results in lung lymphocyte accumulation and bronchus-associated lymphoid tissue formation.

Authors:  Siva Kumar Solleti; Sorachai Srisuma; Soumyaroop Bhattacharya; Javier Rangel-Moreno; Kaiser M Bijli; Troy D Randall; Arshad Rahman; Thomas J Mariani
Journal:  FASEB J       Date:  2016-04-08       Impact factor: 5.191

2.  A sphingosine-1-phosphate receptor 1 agonist inhibits tertiary lymphoid tissue reactivation and hypersensitivity in the lung.

Authors:  C A Huppé; P Blais Lecours; A Lechasseur; D R Gendron; A M Lemay; E Y Bissonnette; M R Blanchet; C Duchaine; M C Morissette; H Rosen; D Marsolais
Journal:  Mucosal Immunol       Date:  2017-04-19       Impact factor: 7.313

3.  Lymphatic impairment leads to pulmonary tertiary lymphoid organ formation and alveolar damage.

Authors:  Hasina Outtz Reed; Liqing Wang; Jarrod Sonett; Mei Chen; Jisheng Yang; Larry Li; Petra Aradi; Zoltan Jakus; Jeanine D'Armiento; Wayne W Hancock; Mark L Kahn
Journal:  J Clin Invest       Date:  2019-04-04       Impact factor: 14.808

4.  Induction of pulmonary antibodies against oxidized lipids in mice exposed to cigarette smoke.

Authors:  Danya Thayaparan; Pamela Shen; Martin R Stämpfli; Mathieu C Morissette
Journal:  Respir Res       Date:  2016-08-04

5.  The role of miR-155 in cigarette smoke-induced pulmonary inflammation and COPD.

Authors:  E G De Smet; H P Van Eeckhoutte; F Avila Cobos; E Blomme; F M Verhamme; S Provoost; S E Verleden; K Venken; T Maes; G F Joos; P Mestdagh; G G Brusselle; K R Bracke
Journal:  Mucosal Immunol       Date:  2019-12-09       Impact factor: 7.313

6.  Pneumocystis-Driven Inducible Bronchus-Associated Lymphoid Tissue Formation Requires Th2 and Th17 Immunity.

Authors:  Taylor Eddens; Waleed Elsegeiny; Maria de la Luz Garcia-Hernadez; Patricia Castillo; Giraldina Trevejo-Nunez; Katelin Serody; Brian T Campfield; Shabaana A Khader; Kong Chen; Javier Rangel-Moreno; Jay K Kolls
Journal:  Cell Rep       Date:  2017-03-28       Impact factor: 9.423

Review 7.  The formation and function of tertiary lymphoid follicles in chronic pulmonary inflammation.

Authors:  Koshika Yadava; Paul Bollyky; Melissa A Lawson
Journal:  Immunology       Date:  2016-08-16       Impact factor: 7.397

8.  Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis.

Authors:  Daryle J DePianto; Sanjay Chandriani; Alexander R Abbas; Guiquan Jia; Elsa N N'Diaye; Patrick Caplazi; Steven E Kauder; Sabyasachi Biswas; Satyajit K Karnik; Connie Ha; Zora Modrusan; Michael A Matthay; Jasleen Kukreja; Harold R Collard; Jackson G Egen; Paul J Wolters; Joseph R Arron
Journal:  Thorax       Date:  2014-09-12       Impact factor: 9.139

Review 9.  B cells in chronic obstructive pulmonary disease: moving to center stage.

Authors:  Francesca Polverino; Leen J M Seys; Ken R Bracke; Caroline A Owen
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-08-19       Impact factor: 5.464

10.  C-X-C motif chemokine 13 (CXCL13) is a prognostic biomarker of idiopathic pulmonary fibrosis.

Authors:  Louis J Vuga; John R Tedrow; Kusum V Pandit; Jiangning Tan; Daniel J Kass; Jianmin Xue; Divay Chandra; Joseph K Leader; Kevin F Gibson; Naftali Kaminski; Frank C Sciurba; Steven R Duncan
Journal:  Am J Respir Crit Care Med       Date:  2014-04-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.